Lineage Cell Therapeutics, Inc. Business Acquisition, Pro Forma Earnings Per Share, Diluted
Lineage Cell Therapeutics, Inc. (LCTX) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of -$0.49 per share for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-17.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2014-03-17
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2013 was -$0.49.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2012 was -$0.78.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2011 was -$0.33.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|
| 2013-12-31 | -$0.49 10-K · filed 2014-03-17 | |
| 2012-12-31 | -$0.78 10-K · filed 2014-03-17 | -$0.43 10-K · filed 2013-03-18 |
| 2011-12-31 | -$0.33 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |